What does Lynx1 Capital Management LP hold? Q1 2026 13F Holdings & Portfolio

AI Analysis · Q1 2026 · Q1 2026

Lynx1 Capital Management LP filed its latest 13F-HR for Q1 2026. See the latest holdings and position changes below.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight

STOKE THERAPEUTICS INC

$155M4.8M24.5%

GH RESEARCH PLC

$151M10.8M23.9%

CULLINAN THERAPEUTICS INC

$127M9.0M20.1%

AGIOS PHARMACEUTICALS INC

$88M2.6M14.0%

DENALI THERAPEUTICS INC

$36M1.9M5.7%

C4 THERAPEUTICS INC

$18M7.0M2.9%

KORRO BIO INC

$17M1.5M2.8%

TSCAN THERAPEUTICS INC

$8M8.0M1.3%

XENCOR INC

$6M536K1.0%

PRECISION BIOSCIENCES INC

$5M985K0.9%

Filing history loading…